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Abstract
A recent phase 1 trial of the fatty acid amide hydrolase (FAAH) inhibitor BIA 10-2474 led to the 
death of one volunteer and produced mild-to-severe neurological symptoms in four others. 
Although the cause of the clinical neurotoxicity is unknown, it has been postulated, given the 
clinical safety profile of other tested FAAH inhibitors, that off-target activities of BIA 10-2474 
may have played a role. Here, we use activity-based proteomic methods to determine the protein 
interaction landscape of BIA 10-2474 in human cells and tissues. This analysis revealed that the 
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drug inhibits several lipases that are not targeted by PF04457845, a highly selective and clinically 
tested FAAH inhibitor. BIA 10-2474, but not PF04457845, produced substantial alterations in 
lipid networks in human cortical neurons, suggesting that promiscuous lipase inhibitors have the 
potential to cause metabolic dysregulation in the nervous system.
Main text
In January 2016, a first-in-human study of the fatty acid amide hydrolase (FAAH) inhibitor 
BIA 10-2474 led to the death of one volunteer and the hospitalization of four others (1–4). 
All patients manifested mild-to-severe neurological symptoms (3). FAAH is a membrane-
bound serine hydrolase that degrades the endocannabinoid anandamide and related amidated 
lipids (5–8). Three explanations for the clinical neurotoxicity of BIA 10-2474 have been 
proposed: (i) errors may have occurred in the clinical trial itself, either in the manufacturing 
or handling of the compound or in the conduct of the trial; (ii) through its inhibitory effects 
on FAAH, BIA 10-2474 may have produced high levels of long-chain fatty acid amides 
(e.g., anandamide) and their oxygenated metabolites, which could potentially overstimulate 
cannabinoid CB1 (8), TRPV1 (9), and/or NMDA receptors (10); or (iii) BIA 10-2474 and/or 
its metabolites might have off-target activities. The first hypothesis was dismissed by the 
French authorities (4). The second hypothesis is considered unlikely because other FAAH 
inhibitors, such as PF04457845, have exhibited favorable safety profiles in Phase 1 and 2 
clinical trials (11, 12). The third hypothesis has not been directly evaluated, because little or 
no information is available regarding the protein interaction profile of BIA 10-2474 (1).
BIA 10-2474 (Fig. 1A) contains an electrophilic imidazole urea that may react with the 
nucleophilic serine of FAAH and other serine hydrolases to form covalent and irreversible 
adducts. We predicted that the serine hydrolase targets of BIA 10-2474 could be identified 
using chemical proteomic methods (13–15); this would allow us to compare its selectivity 
profile to that of PF04457845 (Fig. 1A), a FAAH inhibitor that progressed to Phase 2 trials 
without serious adverse events (16). We first synthesized BIA 10-2474, along with BIA 
10-2639, a confirmed metabolite in which the N-oxide of BIA 10-2474 has been reduced to 
a pyridine (4) (Fig. 1A), in two independent labs and confirmed their structures by 1H- 
and 13C-NMR and high-resolution mass spectrometry (17). Both independently generated 
sets of compounds displayed equivalent activities in the biological assays described from 
here forward.
Our initial experiments using substrate hydrolysis assays revealed that BIA 10-2474 showed 
weak in vitro inhibitory activity against human and rat FAAH, displaying IC50 values ≥ 1 
μM (Fig. 1B, Fig. S1, and Table S1). Consistent with previous reports (6, 16), PF04457845 
potently inhibited FAAH with IC50 values of ~1–10 nM (Fig. 1B and Table S1). In contrast, 
BIA 10-2474 exhibited greatly improved potency in cellular assays (in situ), blocking human 
FAAH activity in transfected HEK293T (human embryonic kidney) cells with IC50 values of 
0.05–0.07 μM (Fig. 1B). BIA 10-2474 and PF04457845 did not interact with other proteins 
of the endocannabinoid system or with the endocannabinoid-binding TRP ion channels 
(Tables S2 and S3).
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We also created alkynylated analogues of BIA 10-2474 – AJ167, AJ179 and AJ198 – and 
found that two of these compounds (AJ179 and AJ198) labeled mouse and human FAAH in 
brain lysates, as detected by coupling to azide fluorescent reporter groups via copper(I)-
catalyzed azide-alkyne cycloaddition (“click”) chemistry (Fig. S2) (18). This finding, 
coupled with the time-dependent inhibition of FAAH displayed by BIA 10-2474 (Table S1), 
provides strong evidence that BIA 10-2474 and related imidazole ureas exhibit an 
irreversible mode of action.
To investigate the serine hydrolase interaction landscape of BIA 10-2474, we used activity-
based protein profiling (ABPP), a chemical proteomic method that employs active site-
directed chemical probes (e.g., fluorophosphonates (FPs) or beta-lactones for serine 
hydrolases) to assess the functional state of entire enzyme classes directly in native 
biological systems (13, 15). When coupled to fluorescent reporter groups, ABPP probes 
enable visualization of enzyme activities in complex proteomes by SDS-PAGE and in-gel 
fluorescence scanning. When coupled to a biotin reporter group, ABPP probes enable 
affinity enrichment and identification of enzyme activities by mass spectrometry (MS)-based 
proteomics. In both formats, ABPP serves as a versatile method to assess target engagement 
and proteome-wide selectivity for small-molecule inhibitors. Gel-based ABPP using a 
fluorescent FP probe (FP-TAMRA) confirmed the relative in vitro and in situ potencies of 
BIA 10-2474 and PF04457845 for human FAAH in transfected HEK293T cell preparations 
(Fig. 1C). The reason for the increased cellular activity of BIA 10-2474 is unclear, but could 
reflect cellular accumulation of the compound, which has been observed for other types of 
enzyme inhibitors (19).
Initial ABPP studies were performed in the human colon carcinoma cell line SW620, which 
expresses a wide diversity of endogenous serine hydrolase activities, including FAAH and 
FAAH2. Isotopically heavy and light amino acid-labeled SW620 cells were treated with 
DMSO or drug (BIA 10-2474 or PF04457845; 0.2 or 10 μM each for 4 h, or 50 μM each for 
24 h) and then lysed and treated with a biotinylated FP probe. The samples are then 
combined, and subjected to streptavidin enrichment and quantitative LC-MS analysis, in 
which proteins displaying heavy:light ratios of > 2.0 were designated as drug-inhibited 
targets. We focused on human cell studies and tested a broad range of inhibitor 
concentrations because the deleterious neurological effects of BIA 10-2474 were observed in 
humans, but not other mammals, and occurred at drug doses that were 10 to 50 times higher 
than that required for blockade of FAAH activity in the clinical trial participants (4).
Our MS-based ABPP studies confirmed that both BIA 10-2474 and PF04457845 fully 
engaged human FAAH at all tested concentrations (0.2, 10, and 50 μM) (Fig. 2A, B and Fig. 
S3). Both drugs showed good selectivity for FAAH at the lowest concentration tested (0.2 
μM; Fig. S3). PF04457845 maintained this selectivity profile at higher concentrations, 
displaying only a single major off-target – the homologous enzyme FAAH2 – among ~60 
quantified serine hydrolases, consistent with previous studies (16). In contrast, BIA 10-2474 
and its metabolite BIA 10-2639 exhibited numerous off-targets across the tested drug 
concentration range, including FAAH2 and several lipid hydrolases, such as ABHD6, 
ABHD11, LIPE, and PNPLA6 and xenobiotic drug-metabolizing enzymes CES1, CES2, 
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and CES3 (Fig. 2A, B). Some of these off-targets, such as ABHD6 and CES2, were near-
completely inhibited (>90%) at both 10 μM and 50 μM concentrations of BIA 10-2474.
Representative off-targets of BIA 10-2474 were recombinantly expressed in HEK293T cells 
and verified to engage BIA 10-2474 by gel-based ABPP (Fig. 2C). These experiments also 
confirmed the relative potency of off-targets mapped by MS-based ABPP, with BIA 10-2474 
exhibiting greater inhibitory activity against ABHD6 and CES2 compared to PNPLA6. In 
contrast, none of the recombinantly expressed enzymes were inhibited by PF04457845 
except FAAH2 (Fig. 2C).
Our chemical proteomic data, taken together, demonstrated that both BIA 10-2474 and its 
major metabolite BIA 10-2639 cross-react with several human serine hydrolases that do not 
interact with PF04457845 (Tables 1 and S4). One possible contributing factor to this broader 
interaction profile is the greater intrinsic reactivity of BIA 10-2474 compared to 
PF04457845, which is reflected in their respective rates of methanolysis (Fig. S4). We also 
note that human CES2 and ABHD6 were both more potently inhibited by BIA 10-2474 and 
BIA 10-2639 compared to the mouse orthologs of these enzymes (Table S2), indicating the 
potential for species differences in the off-target-mediated activities of these compounds.
Many of the off-targets of BIA 10-2474 are involved in cellular lipid metabolism (20, 21) 
and most (with the exception of FAAH2) show substantial expression in human brain tissue 
(Fig. S5). While the poor in vitro activity displayed by BIA 10-2474 limited our ability to 
identify off-targets in brain tissue lysates, we were able to confirm cross-reactivity of this 
drug with both FAAH and ABHD6 in human frontal cortex proteome (post-mortem samples 
acquired from three male donors who were 49, 50, and 80 years of age and who were not 
associated with the BIA 10-2474 trial) (Fig. S6). We also observed several of the off-targets 
of BIA 10-2474 by ABPP of human cortical neurons derived from induced pluripotent stem 
cells (Fig. S7).
We next tested whether prolonged exposure to BIA 10-2474 altered lipid metabolism in 
human cortical neurons. We performed targeted lipidomic analysis of human cortical 
neurons cultures treated with vehicle (DMSO) or BIA 10-2474 (50 μM) at a concentration 
that was ~20x above the Cmax observed in the human clinical trial (22). In total the levels of 
161 lipid species were quantified, of which 54 showed a fold change of ≥ 1.20 or ≤ 0.80 
when using a Benjamini–Hochberg false discovery rate ≤ 25% (Fig. 3A and Table S5). The 
lipids affected by BIA 10-2474 included FAAH substrates (N-acylethanolamines), as well as 
several other lipid classes, including triglycerides, monoacylglycerols, 
(lyso)phosphatidylcholines, free fatty acids and plasmalogens. In contrast, treatment of 
human cortical neuron cultures with PF04457845 (1 μM), also tested at a concentration that 
was 20x above the clinical Cmax for the drug (11), produced a more restricted profile of lipid 
changes, predominantly corresponding to the expected elevations of N-acylethanolamines 
(Fig. 3B).
In summary, we have found that BIA 10-2474 acts as an irreversible inhibitor of FAAH that 
displays greater cross-reactivity with human serine hydrolases than the clinically tested 
FAAH inhibitor PF04457845. Many of the off-targets of BIA 10-2474 are lipolytic enzymes, 
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raising the possibility that disruption of cellular lipid networks may have contributed to the 
compound’s neurotoxicity. Notably, disruption of neuronal lipid metabolism by inhibition of 
PNPLA6, one of the off-target proteins of BIA 10-2474 identified herein, has previously 
been linked to organophosphate-based neurotoxicity in humans (21, 23–25), and recessive 
loss-of-function mutations in the pnpla6 gene are responsible for a broad spectrum of 
neurodegenerative disorders (26, 27).
While our data provide information about the selectivity of BIA 10-2474, they do not allow 
us to conclude that inhibition of one or more of the identified off-target proteins is 
responsible for the clinical neurotoxicity caused by this drug. Nor can we exclude the 
possibility that non-covalent interactions of BIA 10-2474 or its metabolites with other 
proteins might have contributed to the reported clinical effects (28). Regardless, our study 
highlights the general utility of ABPP as a versatile chemical proteomic method to assess 
on-target engagement and off-target activity of covalent drugs to guide therapeutic 
development.
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Fig. 1. Comparison of human FAAH inhibition by BIA 10-2474, BIA 10-2639, and PF04457845
(A) The structures of BIA 10-2474, the metabolite BIA 10-2639, and PF04457845. (B) 
Inhibition of human FAAH in HEK293T cell lysates (in vitro) or intact cells (in situ) as 
measured using an anandamide substrate hydrolysis assay. (C) In vitro and in situ inhibition 
of human FAAH as measured by competitive gel-based ABPP. Top panels, HEK293T cell 
lysates (in vitro) or intact cells (in situ) recombinantly expressing human FAAH were 
pretreated with compound or DMSO (in vitro: 30 min, 37 °C in situ: 4 h, 37 °C). FAAH 
activity was measured by reactivity with the serine hydrolase-directed probe 
fluorophosponate-rhodamine and visualization of signals by gel-based ABPP. Bottom 
panels, Corresponding IC50 curves for gel-based ABPP data shown in Top Panels. N = 3 
independent experiments per group.
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Fig. 2. Quantitative proteomic analysis of serine hydrolase targets of FAAH inhibitors in human 
cells
(A, B) MS-based ABPP of serine hydrolase activities in SW620 cells treated with DMSO or 
FAAH inhibitor. Shown in (A) are BIA 10-2474, BIA 10-2639, and PF04457845 (10 μM, 4 
h, 37 °C). Shown in (B) are BIA 10-2474 and PF04457845 (50 μM, 24 h, 37 °C). Data are 
expressed as median SILAC ratio values for all isotopic peptide pairs quantified per protein 
from two biological replicates. (C) Confirmation of representative off-targets of BIA 
10-2474 by gel-based ABPP of recombinantly expressed enzymes in HEK293T cells.
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Fig. 3. BIA 10-2474, but not PF04457845, causes substantial alterations in lipid metabolism in 
human cortical neurons
(A, B) Cortical neurons were treated with DMSO (A, B), BIA 10-2474 (50 μM) (A) or with 
PF04457845 (1 μM) (B) and analyzed by MS-based lipidomics after 48 h. X-axis denotes 
fold change of lipid species in the inhibitor-treated cells vs DMSO-treated cells. Lipidomic 
data are presented as a volcano plot and lipids with a fold change (FC) threshold of ≥1.20 or 
≤0.80 and Benjamini–Hochberg false discovery rate (FDR) ≤ 25% are represented by 
colored circles distinguished by lipid class. Data represent average values from at least two 
independent experiments.
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Table 1
In vitro and in situ inhibitory potencies of BIA 10-2474, BIA 10-2639, and PF04457845 
against FAAH and representative off-targets
Measurements were made by gel-based ABPP of HEK293T cells recombinantly expressing the indicated 
human serine hydrolases. Data represent inhibitor treatment of cells for 4 h with the exception of PNPLA6, 
where data represent inhibitor treatment of cells for 24 h. Data represent average values from three 
independent experiments per group. See Table S4 for error measurements related to IC50 values.
Enzyme Treatment
IC50 (μM)
BIA 10-2474 BIA 10-2639 PF04457845
FAAH in vitro 7.5 4.1 0.0040
FAAH in situ (4 h) 0.049 0.049 0.011
FAAH2 in situ (4 h) 0.40 0.10 0.59
ABHD6 in situ (4 h) 0.081 0.079 >10
CES2 in situ (4 h) 2.0 0.63 >10
ABHD11 in situ (4 h) >10 2.3 >10
PNPLA6 in situ (24 h) 11 N.D. >50
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